Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Director | June 24, 2026 | June 26, 2026 |
| Nkarta, Inc.NKTX · Entity 6346 | Director | June 08, 2022 | June 10, 2022 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Director | June 03, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.54 · Expires 2036-06-23 | Direct | 30,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Nkarta, Inc.
Report date June 08, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2032-06-07 | Direct | 16,000 |
Reported balance
After 2022-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-08 · Grant · Acquired 16,000 · Balance 16,000 F1: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).
Relay Therapeutics, Inc.
Report date June 03, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.79 · Expires 2034-06-02 | Direct | 102,225 |
Reported balance
After 2024-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-03 · Grant · Acquired 102,225 · Balance 102,225 F1: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Synthorx, Inc.
Report date January 23, 2020 · Filed January 24, 2020
Section 16 reporting ended · disclosed 2020-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 215,595 |
Reported balance
After 2020-01-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-01-08 · Gift · Disposed 80,706 · Balance 215,595 |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-01-23 · Other · Disposed 220,595 · Balance 0 F1: Includes 5,000 shares of Common Stock that were acquired by the Reporting Person on January 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | IndirectBy Laura K. Shawver Trust DTD 3/20/2000 | 0 |
Reported balance
After 2020-01-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-01-23 · Other · Disposed 25,000 · Balance 0 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2028-05-16 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-23 · Disposition to issuer · Disposed 293,177 · Balance 0 F2: This option, which provided for vesting of 27,695 shares on April 12, 2019, with the remaining 363,944 shares vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $19,663,381.39, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2027-12-06 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-23 · Disposition to issuer · Disposed 172,264 · Balance 0 F3: This option, which provided for vesting of 25% of the shares one year after November 27, 2017, with the balance vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $11,605,425.68, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2028-12-05 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-23 · Disposition to issuer · Disposed 385,185 · Balance 0 F4: This option, which provided for vesting of 33.333% of the shares on December 18, 2019, with 66.667% of the shares subject to the option vesting upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $21,955,545.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 5,000 shares of Common Stock that were acquired by the Reporting Person on January 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.
F2: This option, which provided for vesting of 27,695 shares on April 12, 2019, with the remaining 363,944 shares vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $19,663,381.39, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
F3: This option, which provided for vesting of 25% of the shares one year after November 27, 2017, with the balance vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $11,605,425.68, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
F4: This option, which provided for vesting of 33.333% of the shares on December 18, 2019, with 66.667% of the shares subject to the option vesting upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $21,955,545.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 20:15 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $10.54 | $0.00 |
DisclosureSEC source: 0001551891-26-000002 · form4-06262026_040601.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001415889-25-018382 · form4-06272025_040603.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| April 07, 2025 Filed Apr 8, 2025 20:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,493 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001415889-25-010395 · form4-04082025_040401.xml · derivative · entry 5 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,062 Underlying: Common Stock · 27,493 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| April 07, 2025 Filed Apr 8, 2025 20:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,509 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001415889-25-010395 · form4-04082025_040401.xml · derivative · entry 4 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,555 Underlying: Common Stock · 22,509 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| April 07, 2025 Filed Apr 8, 2025 20:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,002 | $12.30 | $615,074.60 |
DisclosureSEC source: 0001415889-25-010395 · form4-04082025_040401.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024. F2 · price: The weighted average sale price for the transaction reported was $12.301 and the range of prices were between $12.0063 and $12.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 07, 2025 Filed Apr 8, 2025 20:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 27,493 | $4.85 | $133,341.05 |
DisclosureSEC source: 0001415889-25-010395 · form4-04082025_040401.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2025 Filed Apr 8, 2025 20:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 22,509 | $4.85 | $109,168.65 |
DisclosureSEC source: 0001415889-25-010395 · form4-04082025_040401.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 22:12 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,600 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001415889-25-007438 · form4-03072025_100311.xml · derivative · entry 6 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,064 Underlying: Common Stock · 49,600 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 22:12 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 49,600 | $11.21 | $556,045.76 |
DisclosureSEC source: 0001415889-25-007438 · form4-03072025_100311.xml · nonDerivative · entry 4 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024. F2 · price: The weighted average sale price for the transaction reported was $11.2106 and the range of prices were between $11.00 and $11.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 22:12 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 49,600 | $4.85 | $240,560.00 |
DisclosureSEC source: 0001415889-25-007438 · form4-03072025_100311.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 22:12 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001415889-25-007438 · form4-03072025_100311.xml · derivative · entry 5 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,664 Underlying: Common Stock · 400 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 22:12 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 400 | $11.00 | $4,400.00 |
DisclosureSEC source: 0001415889-25-007438 · form4-03072025_100311.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 22:12 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 400 | $4.85 | $1,940.00 |
DisclosureSEC source: 0001415889-25-007438 · form4-03072025_100311.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,936 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001415889-25-002955 · form4-02042025_040201.xml · derivative · entry 5 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,064 Underlying: Common Stock · 40,936 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,064 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001415889-25-002955 · form4-02042025_040201.xml · derivative · entry 4 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,064 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $12.31 | $615,565.00 |
DisclosureSEC source: 0001415889-25-002955 · form4-02042025_040201.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024. F2 · price: The weighted average sale price for the transaction reported was $12.3113 and the range of prices were between $11.9732 and $12.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 40,936 | $4.85 | $198,539.60 |
DisclosureSEC source: 0001415889-25-002955 · form4-02042025_040201.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 9,064 | $3.15 | $28,551.60 |
DisclosureSEC source: 0001415889-25-002955 · form4-02042025_040201.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 219,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 23:24 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001415889-25-001053 · form4-01072025_110124.xml · derivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,064 Underlying: Common Stock · 50,000 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 23:24 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $11.10 | $555,065.00 |
DisclosureSEC source: 0001415889-25-001053 · form4-01072025_110124.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024. F2 · price: The weighted average sale price for the transaction reported was $11.1013 and the range of prices were between $11.00 and $11.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 23:24 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 50,000 | $3.15 | $157,500.00 |
DisclosureSEC source: 0001415889-25-001053 · form4-01072025_110124.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,772 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · derivative · entry 14 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,064 Underlying: Common Stock · 14,772 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 14,772 | $13.75 | $203,109.09 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · nonDerivative · entry 9 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024. F5 · price: The weighted average sale price for the transaction reported was $13.7496 and the range of prices were between $13.39 and $14.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 14,772 | $3.15 | $46,531.80 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · nonDerivative · entry 8 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 62,378 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · derivative · entry 13 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,836 Underlying: Common Stock · 62,378 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,606 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · derivative · entry 12 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,606 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 87,984 | $13.26 | $1,166,896.60 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · nonDerivative · entry 7 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024. F4 · price: The weighted average sale price for the transaction reported was $13.2626 and the range of prices were between $12.92 and $13.62. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 62,378 | $3.15 | $196,490.70 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · nonDerivative · entry 6 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 298,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 25,606 | $1.27 | $32,519.62 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · nonDerivative · entry 5 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 67,616 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · derivative · entry 11 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,616 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Due to a clerical error, the total number of shares subject to this option grant was underreported by one share on the Reporting Person's Form 3 and is corrected on this filing. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,628 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · derivative · entry 10 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,606 Underlying: Common Stock · 29,628 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 901 | $14.34 | $12,921.87 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · nonDerivative · entry 4 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024. F3 · price: The weighted average sale price for the transaction reported was $14.3417 and the range of prices were between $14.2761 and $14.375. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 96,343 | $13.55 | $1,305,823.39 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,247 F1 · kind: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024. F2 · price: The weighted average sale price for the transaction reported was $13.5539 and the range of prices were between $13.27 and $14.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 29,628 | $1.27 | $37,627.56 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:40 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 67,616 | $1.27 | $85,872.32 |
DisclosureSEC source: 0001415889-24-028350 · form4-12042024_091203.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 277,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001415889-24-018016 · form4-06242024_050616.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 00:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 102,225 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0000950170-24-069559 · ownership.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,225 Underlying: Common Stock · 102,225 shares Expires 2034-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 00:04 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 97,003 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-048254 · doc4.xml · derivative · entry 5 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,235 Underlying: Common Stock · 97,003 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 00:04 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,997 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-048254 · doc4.xml · derivative · entry 4 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,997 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 00:04 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 100,000 | $7.71 | $770,520.00 |
DisclosureSEC source: 0001209191-23-048254 · doc4.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.24 to $8.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 00:04 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 97,003 | $1.27 | $123,193.81 |
DisclosureSEC source: 0001209191-23-048254 · doc4.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 310,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 00:04 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 2,997 | $1.27 | $3,806.19 |
DisclosureSEC source: 0001209191-23-048254 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 21:05 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,897 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-044845 · doc4.xml · derivative · entry 6 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,997 Underlying: Common Stock · 18,897 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 21:05 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 18,897 | $7.06 | $133,471.40 |
DisclosureSEC source: 0001209191-23-044845 · doc4.xml · nonDerivative · entry 4 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.96 to $7.22, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 21:05 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 18,897 | $1.27 | $23,999.19 |
DisclosureSEC source: 0001209191-23-044845 · doc4.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 229,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:05 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,017 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-044845 · doc4.xml · derivative · entry 5 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,894 Underlying: Common Stock · 26,107 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:05 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 26,107 | $7.01 | $183,017.90 |
DisclosureSEC source: 0001209191-23-044845 · doc4.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.90 to $7.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:05 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 26,107 | $1.27 | $33,155.89 |
DisclosureSEC source: 0001209191-23-044845 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 22:03 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,281 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-23-044534 · doc4.xml · derivative · entry 6 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,001 Underlying: Common Stock · 36,281 shares Expires 2030-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 22:03 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 36,281 | $7.09 | $257,264.94 |
DisclosureSEC source: 0001209191-23-044534 · doc4.xml · nonDerivative · entry 4 Shawver Laura · CIK 0001551891 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,346 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.95 to $7.23, inclusive. The Reporting Person undertakes to provide the the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.